GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 85.57B +41.7% |
| Revenue (ttm) | 32.67B +4.1% |
| Net Income | 5.72B +122.0% |
| EPS | 1.39 +123.2% |
| Shares Out | 3.77B |
| PE Ratio | 16.34 |
| Forward PE | 12.62 |
| Dividend | 0.72 (3.22%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 202,311 |
| Average Volume | 10,271,751 |
| Open | 2,252.00 |
| Previous Close | 2,268.00 |
| Day's Range | 2,249.00 - 2,263.00 |
| 52-Week Range | 1,242.50 - 2,282.00 |
| Beta | 0.27 |
| RSI | 79.27 |
| Earnings Date | Feb 4, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial StatementsNews
GSK's HIV Treatment Achieves Superior Results in Phase III Trial
GSK's HIV Treatment Achieves Superior Results in Phase III Trial
Ex-Dividend Reminder: Shell, Patria Investments and Glaxosmithkline
Looking at the universe of stocks we cover at Dividend Channel, on 2/20/26, Shell plc (Symbol: SHEL), Patria Investments Limited - Class Ahares (Symbol: PAX), and Glaxosmithkline plc (Symbol: GLAXF) w...
GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
PHILADELPHIA--(BUSINESS WIRE)--GSK's AREXVY associated with reductions in certain RSV-related risks, real world study shows.
GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade)
GSK's Arexvy Vaccine Shows Strong Effectiveness in Real-World Study
GSK's Arexvy Vaccine Shows Strong Effectiveness in Real-World Study
GSK says RSV shot Arexvy lowers risk of CV events, asthma, and COPD
GSK says real-world data shows Arexvy cut RSV hospitalizations and lowered heart attack/stroke, asthma and COPD flare-ups in adults 60+. Read more here.
GSK wins approval of Exdensur in Europe for severe asthma
GSK Reports Promising Data for RSV Vaccine Effectiveness
GSK Reports Promising Data for RSV Vaccine Effectiveness
Europe Clears GSK's New Twice-Yearly Asthma Treatment
The European Commission on Tuesday approved GSK plc’s (NYSE: GSK) Exdensur (depemokimab) in two indications, including: As an add-on maintenance treatment for severe asthma with type 2 inflammation, ...
GSK Begins Fourth Tranche Of Up To GBP 0.45 Bln Share Buyback Under GBP 2 Bln Programme
(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Tuesday that it is commencing the fourth tranche of its 2 billion pounds share buyback Programme announced last year. The company will buy...
Noteworthy ETF Inflows: FENI, GSK, BTI, RIO
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Fidelity Enhanced International ETF (Symbol: FENI) where we have detec...
Is GSK PLC Gaining or Losing Market Support?
GSK PLC's (NYSE: GSK) short interest as a percent of float has risen 18.92% since its last report. According to exchange reported data, there are now 17.55 million shares sold short , which is 0.88% ...
GSK's Arexvy Awaits Approval in China for RSV Prevention in Seniors
GSK's Arexvy Awaits Approval in China for RSV Prevention in Seniors
GSK’s Arexvy RSV vaccine accepted for regulatory review in China for seniors
Pharma sector stocks today, Feb 10: Pfizer rally 9%, GSK Pharma up 4.12%, Divis Laboratories rises 1.47%
The Indian pharmaceutical sector showed mixed performance on February 10, 2026, as of around 10:05 AM IST. The data provided...
GSK (GSK) Shares Climb Amid Positive Developments and EU Approval
GSK (GSK) Shares Climb Amid Positive Developments and EU Approval
GSK shares uptick for seven consecutive sessions
GSK (GSK) Gains EU Approval for Expanded Use of Nucala in COPD Treatment
GSK (GSK) Gains EU Approval for Expanded Use of Nucala in COPD Treatment
GSK wins EU nod to expand Nucala for COPD
GSK Gains European Approval for Nucala in COPD Treatment
GSK Gains European Approval for Nucala in COPD Treatment
GSK Wins EU Approval For Nucala In COPD Treatment
(RTTNews) - GSK plc (GSK) on Friday said the European Commission has approved Nucala as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD).
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT ...
GSK (GSK) Q3 2025 Earnings Call Transcript
GSK (GSK) Q3 2025 Earnings Call Transcript
3 International Stocks to Buy for 2026
Plus, which countries and sectors look most attractive to invest in today. In this bonus episode of The Morning Filter podcast, host Susan Dziubinski talks with Morningstar chief Europe markets strate...